09:00 - 17:30 EST | 6.00 - 14.30 PST

* Please note that the following agenda timings are Eastern Standard Time.  

For full agenda session details and Pacific Standard Times, please download the full event guide here

8:20 am Chair’s Opening Remarks

Assessing Current Modelling Limitations & Emerging Trends to Drive Clinical Success

8:30 am Combination of a Multimeric Anti-DR5 IgM Antibody with Targeted Agents Induces Synergistic Tumor Cytotoxicity in Vitro & in Vivo


  •  Death receptor 5 (DR5) is activated upon receptor trimerization and induces cell death. IGM-8444 is a multivalent IgM antibody that efficiently clusters DR5 to induce potency tumor cytotoxicity
  • IGM-8444 has a good preclinical safety profile, enabling opportunities for rational combinations with targeted agents
  • Synergistic combinations were identified in vitr

9:00 am Reserved for the Jackson Laboratory

9:30 am Translatability at a Glance: Combined Gene Edited & Engineered Cellular Therapies for Solid Tumors

  • Khalid Shah Vice Chairman at BWH, Harvard Medical School


  • Creating and characterizing cellular therapies for targeting multiple cell surface receptors on tumor cells and TME
  • Testing the efficacy of targeted cellular therapies in translatable tumor models
  • Defining a roadmap towards clinical translation

10:00 am Patient-Derived Cell (PDC) Models as a Tool to Assess Cancer Therapeutic Efficacy Across the Drug Development Life Cycle


  • PDC model development and characterization
  • Clinical response predictivity
  • HTS/HCI applications to assess cancer therapeutic efficacy, mechanism of action and patient stratification

10:30 am Morning Break & Structured Networking

Drug Discovery

Optimizing Technologies to Support Pre- Clinical Models

11:15 am Panel Discussion: Utilizing RNA-Seq for Better Pre-Clinical Predictions & Patient Identification


  • Screening for actionable targets based on targeted RNA-sequencing to make a more accurate prediction of drug efficacy
  • How to preserve the complexity of tumor biology in models?
  • Can we use RNAseq to understand MoA?
  • Can we use baseline RNAseq readouts as patients selection? Is this practical with a gene signature, or do we need to limit this to 1-2 genes to make this practical in clinical trials?

11:45 am Humanized Mouse Model as a Translational Tool for Immunotherapy in Oncology

  • Frank Sun Senior Principal Scientist, Oncology Pharmacology, Sanofi


  • Engineering human target in huPBMC GvHD model to construct a clinic translational model
  • Deepen understanding of tumor biology and therapeutic response of multiple specific Nanobodies
  • Donor selection and HLA match for improving treatment response

Drug Development

Exploring Approaches to Dosing & Combination Administration Methods

11:15 am Targeting c-MET in Combination with Radiation is Effective in MET-Fusion Driven High- Grade Glioma

  • Marc Zuckermann Group Leader Preclinical Modeling, German Cancer Research Center (DKFZ)


  • Inhibitor and radiation regimen selection for combinatorial in vivo trials
  • Validating preclinical results in multiple mouse models
  • Complementing in vivo data with PK and in vitro analyses

11:45 am Combination Therapy to Outsmart RASAddicted Cancer – Informing Clinical Strategy with Preclinical Modeling

  • Jingjing Jiang Senior Director, Translational Research, Revolution Medicines


  • Identify biomarkers that can help direct the “right combination regimen” to the “right patients”
  • Define upfront combination regimens that can prevent/ delay emergent resistance mechanisms to RevMed RAS(ON) inhibitors
  • Understand if/how we can translate learnings between distinct RAS mutations and cancer histotypes

12:15 pm Networking Lunch

1:15 pm Session Reserved for genOway

Tackling Metastasis: Modelling, Prevention & Treatment

1:45 pm Modeling Bone Metastasis of Prostate Cancer

  • Juan Arriaga Assistant Professor – Department of Oncological Sciences & Urology, Icahn School of Medicine at Mount Sinai


  • Develop mouse models to understand the way tumors metastasize and respond to therapy
  • What determines metastatic competency? Can we predict this by studying primary tumors?
  • What is the role of biomarkers to predict disease progression?

2:15 pm Session Reserved for Labcorp

2:30 pm Afternoon Break

3:00 pm Session Reserved for GemPharmatech

3:30 pm Developing Clinically Translatable Models that Accurately Represent Patient Metastasis

  • Anita Seshire Head Of Laboratory in Exploratory Cancer Research, Translational Innovation Platform Oncology- Immunooncology, Merck EMD Serono


  • Understanding physiological routes of metastasis
  • Identifying factors that influence dissemination
  • Understanding how the microenvironment contributes to metastasis

4:00 pm Session Reserved for Biocytogen

4:30 pm Chair’s Closing Remarks & End of Conference Day One

4:45 pm 10th Anniversary Poster & Award Session